Market Monitor

J&J’s Multiple Myeloma Therapies Impress with New Data at EHA26

Johnson & Johnson presented new data for its approved multiple myeloma (MM) therapies, Talvey (talquetamab) and Tecvayli (teclistamab-cqyv), at the European...

BeOne Medicines' Oral Beqalzi and Brukinsa Combination Shows Promise in First-Line CLL/SLL

BeOne Medicines presented promising results for its all-oral combination of Beqalzi (BCL2 inhibitor) and Brukinsa (BTK inhibitor) as a first-line treatment for...

Lilly reports Phase III BRUIN CLL-322 trial results for Jaypirca combo

Eli Lilly and Company announced positive results from its Phase III BRUIN CLL-322 trial, evaluating Jaypirca (pirtobrutinib) combined with venetoclax and...

DemeRx Cleared by FDA for First U.S. Clinical Trial of Noribogaine

DemeRx is launching the first U.S. clinical trial for its ibogaine-derived drug candidate, noribogaine, following FDA clearance for first-in-human testing in...

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Elicio Therapeutics reported results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in adjuvant mKRAS-driven pancreatic cancer. The study did not meet its...

Neumora discards depression asset, lays off staffers after pair of late-stage flops

Neumora Therapeutics is laying off 35% of its workforce and discontinuing its oral drug candidate, navacaprant, for major depressive disorder (MDD) after it...